

Seizing opportunities

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.



At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES

	2008
Sales	US\$ 777 million
EBITDA, adjusted*	US\$ 317 million
EBITDA margin, adjusted*	40.8 %
Employees (December 31, full-time equivalent)	1,487
Production facilities	3
Number of products	> 100
Market share	~17 %

* Non-GAAP item